医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Open Monoclonal Technology Provides Important Intellectual Property Update

2014年04月23日 AM07:00
このエントリーをはてなブックマークに追加


 

PALO ALTO, Calif.

Open Monoclonal Technology, Inc. (OMT) today announced issuance of U.S. patent application 8,703,485 related to inactivation of rodent immunoglobulin genes and generation of human antibodies. The issuance came with a patent term extension of 1,228 days and will further strengthen the intellectual property of the company’s OmniAb suite of human therapeutic antibody platforms, including OmniRat®, OmniMouse® and OmniFlic.

The issuance follows the grant of European patent numbers EP2152880 and EP2336329 for similar inventions. In addition, OMT has granted patent protection for related technologies in Australia, China, Hong Kong, Israel and New Zealand as well as pending applications in Canada, Japan, and Singapore.

Dr. Roland Buelow, founder and CEO of OMT, said, “OMT was founded to establish new human therapeutic antibody platforms with freedom to operate in transgenic animals. The initial focus was in rats where the company has platforms for generation of mono- and bispecific antibodies. OMT has also been able to design a mouse system with similar intellectual property benefits. All three platforms are available to OMT’s partners in single licenses, thus offering a convenient and efficient way of creating the optimal antibody format for each scarce therapeutic target, including single antibodies and cocktails as well as naked and drug-conjugated antibodies.”

About Open Monoclonal Technology

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for discovery of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with three transgenic animal platforms, OmniAb™.

OmniRat® is the industry’s first human monoclonal antibody technology based on rats. OMT, in collaboration with Pfizer, has shown that OmniRat has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as a wild-type animals make rat antibodies (Journal of Immunology 2013 Feb 15;190(4):1481-90).

OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. Both deliver human antibodies with high affinity, specificity, expression, solubility and stability.

OmniFlic is the first engineered rat with a fixed light chain for discovery of bispecific, fully human antibodies.

OMT’s antibody platforms have broad freedom to operate and use technology protected by new patents and patent applications. They are available for licensing worldwide for all targets and indications. OMT has granted unlimited platform access to Genentech, Janssen, Merck KGaA, Pfizer, Roche, Symphogen and an undisclosed global pharmaceutical company as well as individual target rights to smaller biotech companies. The Genentech partnership includes forward engineering of OmniRat that is made available to OMT’s partners. OMT’s platforms can also be accessed via China-based WuXi AppTec as part of their global biologics discovery and development services and US-based Antibody Solutions for cost-efficient antibody creation and characterization.

CONTACT

Open Monoclonal Technology, Inc.
Brian Lundstrom, +1 775-420-7750
Chief
Business Officer
bl@omtinc.net
www.omtinc.net

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表